← 返回前沿论文

GSDMB 作为透明细胞肾细胞癌的治疗和预后靶点:来自焦亡相关基因分析的见解

英文原题:GSDMB as a Therapeutic and Prognostic Target in Clear Cell Renal Cell Carcinoma: Insights From Pyroptosis-Related Gene Analysis.

查看英文原题

GSDMB as a Therapeutic and Prognostic Target in Clear Cell Renal Cell Carcinoma: Insights From Pyroptosis-Related Gene Analysis.

PubMed 2026/07/17(内容时间) Front Biosci (Landmark Ed) Q2 · IF 4.1(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

细胞焦亡相关基因,即 AIM2、CASP5、GSDMB、GSDMD、NLRP7、NOD2、PYCARD、SCAF11 和 NLRP6,是 ccRCC 有前景的预后生物标志物,并可能作为预测患者生存和指导免疫治疗策略的预后生物标志物。

研究思路结论见上方概要

近期研究发现,细胞焦亡是一种独特的程序性细胞死亡形式,与肿瘤结局密切相关。然而,其作为透明细胞肾细胞癌(ccRCC)预后生物标志物的价值尚未完全确立。

使用DESeq2 R包鉴定ccRCC与正常组织之间焦亡相关基因的差异表达。接下来,使用来自The Cancer Genome Atlas队列的数据进行单因素和最小绝对收缩和选择算子(LASSO)Cox回归分析,以建立预后模型。进行单因素和多因素预后分析,以确定在调整临床病理特征后,风险评分是否可以独立预测患者预后。随后构建列线图以估计患者生存概率,支持临床决策。使用来自Clinical Proteomic Tumor Analysis Consortium(CPTAC)数据库的组织蛋白质组学数据评估焦亡相关蛋白的表达。此外,使用Tumor-Immune System Interaction Database(TISIDB)数据库分析免疫细胞浸润,而通过Western blot(WB)和定量PCR(qPCR)实验评估ccRCC细胞系中gasdermin B(GSDMB)的表达,并应用免疫组织化学检测GSDMB和程序性死亡受体 1(PD-1)的水平。

利用与细胞焦亡相关的九个基因(AIM2、CASP5、GSDMB、GSDMD、NLRP7、NOD2、PYCARD、SCAF11和NLRP6),通过单因素Cox和LASSO回归分析,构建了一个预后风险模型。根据中位风险评分,将ccRCC样本分为高风险和低风险两类,Kaplan-Meier分析显示高风险组的生存率较差。时间依赖性受试者工作特征曲线分析证实了该模型对ccRCC预后的预测性能。此外,还开发了带有校准图的列线图,用于预测ccRCC患者的1年、3年和5年生存概率。值得注意的是,这些细胞焦亡相关基因与免疫细胞浸润密切相关,包括细胞毒性细胞、CD56brightNK 细胞和辅助性T细胞。随后,qPCR和WB分析证实ccRCC细胞中GSDMB表达升高,免疫组化显示GSDMB与PD-1表达之间存在强相关性。

展开英文摘要原文

Recent research has identified pyroptosis as a distinct form of programmed cell death that is strongly correlated with tumor outcomes. However, its value as a prognostic biomarker in clear cell renal cell carcinoma (ccRCC) is not yet fully established.

Differential expression of pyroptosis-related genes between ccRCC and normal tissues was identified using the DESeq2 R package. Next, univariate and least absolute shrinkage and selection operator (LASSO) Cox regression analyses using data from The Cancer Genome Atlas cohort were applied to develop a prognostic model. Univariate and multivariate prognostic analyses were conducted to determine whether the risk score could independently predicted patient prognosis after adjustment for clinicopathological characteristics. A nomogram was then constructed to estimate patient survival probability, supporting clinical decision-making. Expression of pyroptosis-related proteins was assessed using tissue proteomic data from the Clinical Proteomic Tumor Analysis Consortium (CPTAC) database. Additionally, the Tumor-Immune System Interaction Database (TISIDB) database was used to analyze immune cell infiltration, whereas gasdermin B (GSDMB) expression in ccRCC cell lines was assessed by Western blot (WB) and quantitative PCR (qPCR) experiments, with immunohistochemistry applied to measure the levels of GSDMB and programmed cell death protein 1 (PD-1).

A prognostic risk model was developed using nine genes related to pyroptosis ( AIM2 , CASP5 , GSDMB , GSDMD , NLRP7 , NOD2 , PYCARD , SCAF11 , and NLRP6 ), employing both univariate Cox and LASSO regression analyses. Based on the median risk score, ccRCC samples were divided into high- and low-risk categories, with Kaplan-Meier analysis revealing poorer survival rates for the high-risk group. Time-dependent receiver operating characteristic curve analysis confirmed the predictive performance of the model for ccRCC prognosis. Furthermore, a nomogram with calibration plots was developed to predict 1-, 3-, and 5-year survival probabilities for patients with ccRCC. Notably, these pyroptosis-related genes were strongly correlated with immune cell infiltration, including cytotoxic cells, CD56bright natural killer cells, and T helper cells. Subsequently, qPCR and WB analyses confirmed elevated GSDMB expression in ccRCC cells, and immunohistochemistry demonstrated a strong correlation between GSDMB and PD-1 expression.

Pyroptosis-associated genes, namely AIM2 , CASP5 , GSDMB , GSDMD , NLRP7 , NOD2 , PYCARD , SCAF11 , and NLRP6 , are promising prognostic biomarkers for ccRCC, and may serve as prognostic biomarkers for predicting patient survival and informing immunotherapy strategies.

论文信息

作者
Li G、Li Y、Xu W、Yan L、Xiang Q、Luo Y、Liu Y、Li Q
单位
Department of Urology, The Fifth Affiliated Hospital, Southern Medical University, 510900 Guangzhou, Guangdong, China.China
期刊
Frontiers in bioscience (Landmark edition)2026 Jul 17
原文标识
PubMed 42530271 · DOI 10.31083/FBL51233